‘Discounting the price of existing drugs to list high-priced new drugs.’

Recently, the pharmaceutical industry has been buzzing with speculations that some companies are voluntarily reducing the price of their original drugs as a fiscal sharing strategy to receive reimbursement.

This strategy, which was considered unimaginable before, is raising concern among generic companies, as the price drop of an original drug will threaten the price competitiveness of its generic items.

According to the industry on the 24th, prices of 15 MSD Korea’s Januvia products and 2 Astellas Korea’s Vesicare products will be discounted from the 1st of next month. All the pricing decisions w